List of Excipients in Branded Drug CALCIUM CHLORIDE

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Hospira Inc	CALCIUM CHLORIDE	calcium chloride	0409-1631	HYDROCHLORIC ACID
Hospira Inc	CALCIUM CHLORIDE	calcium chloride	0409-1631	SODIUM HYDROXIDE
Hospira Inc	CALCIUM CHLORIDE	calcium chloride	0409-1631	WATER

Generic Drugs Containing CALCIUM CHLORIDE

Company	Ingredient	NDC	Excipient
American Regent Inc	calcium chloride	0517-6710	HYDROCHLORIC ACID
American Regent Inc	calcium chloride	0517-6710	SODIUM HYDROXIDE
American Regent Inc	calcium chloride	0517-6710	WATER

What are the Most Frequently-Used Excipients in CALCIUM CHLORIDE?

# Of NDCs	Excipient
9	HYDROCHLORIC ACID
9	SODIUM HYDROXIDE
5	WATER

Calcium Chloride Excipient Strategy and Commercial Opportunities in Pharmaceutical Manufacturing

Last updated: August 27, 2026

Calcium chloride is primarily an active pharmaceutical ingredient in injectable electrolyte products, but it also has selective value as a process aid, tonicity modifier, stabilizer, and calcium source in pharmaceutical and biologic manufacturing. Its molecular composition is old and widely available, so direct product patents provide limited protection. Commercial value is concentrated in GMP-grade supply, sterile manufacturing, ready-to-use presentations, validated impurity control, supply reliability, and formulation-specific know-how.

What is calcium chloride used for in pharmaceutical products?

Calcium chloride is used in pharmaceutical products in two distinct ways:

1. As an active ingredient to treat acute hypocalcemia and related emergency conditions.
2. As an excipient or manufacturing material in selected formulations and production processes.

Calcium chloride injection is a high-concentration calcium product. A typical 10% injection contains 100 mg/mL calcium chloride, equivalent to approximately 27 mg/mL elemental calcium. A 10 mL dose therefore provides about 273 mg elemental calcium, or approximately 6.8 mmol calcium [1].

Its principal pharmaceutical functions include:

Function	Application	Commercial relevance
Active electrolyte	Treatment of acute symptomatic hypocalcemia	Established injectable market
Calcium source	Cell culture and biologic manufacturing	Process-grade supply opportunity
Tonicity modifier	Adjustment of ionic strength and osmolality	Formulation-specific use
Stabilizer or cofactor	Selected protein, enzyme, and biologic systems	Requires compatibility testing
Cross-linking agent	Certain hydrogel and controlled-release systems	Specialty formulation opportunity
Process reagent	Cell transfection, coagulation, and purification workflows	Often purchased as GMP or high-purity material
Nutrient component	Specialized parenteral or culture media	Requires tight elemental and impurity control

Calcium chloride is highly soluble and hygroscopic. These properties support concentrated aqueous solutions but create risks involving moisture control, corrosion, particulate generation, container closure integrity, and compatibility with other formulation components.

Is calcium chloride an active ingredient or an excipient?

Calcium chloride can be either, depending on the finished product and the intended function.

Calcium chloride as an active pharmaceutical ingredient

In injectable products, calcium chloride is generally the active ingredient. FDA labeling identifies calcium chloride injection for acute symptomatic hypocalcemia and other clinical situations requiring rapid calcium replacement [1]. Because intravenous calcium chloride can cause severe tissue injury if extravasated, labeling emphasizes slow administration, appropriate dilution where applicable, and central venous administration for concentrated products.

The active-product market is regulated as a drug product rather than as a conventional inactive ingredient. CMC requirements include assay, identity, elemental calcium content, impurities, sterility, endotoxins, particulate matter, pH, osmolality, container closure integrity, and stability.

Calcium chloride as an excipient

Calcium chloride is used as an excipient when it does not provide the principal therapeutic effect. Potential applications include:

• Adjusting ionic strength in aqueous formulations.
• Modifying osmolality in parenteral products.
• Supplying calcium ions to maintain protein or cellular stability.
• Supporting coagulation-related formulations.
• Acting as a functional reagent in hydrogel or polymer systems.
• Supporting cell-based and biologic manufacturing processes.

The FDA Inactive Ingredient Database is the principal reference for assessing prior use in approved drug products and dosage forms [2]. Presence in the database does not establish universal suitability. The permitted level, route, dosage form, patient population, and formulation context remain relevant.

What formulations are protected by calcium chloride excipient strategy?

Calcium chloride itself is rarely protectable through composition-of-matter patents. Commercial protection is more likely to arise from the formulation architecture, manufacturing process, presentation, or use case.

Sterile injectable formulations

The most commercially relevant formulation variables are:

• Concentration of calcium chloride.
• Elemental calcium delivery.
• Diluent selection.
• pH range.
• Buffer system.
• Compatibility with sodium chloride, dextrose, bicarbonate, phosphate, and other electrolytes.
• Container material.
• Closure system.
• Light protection.
• Low-particulate manufacturing controls.
• Ready-to-use versus concentrate presentation.

Calcium chloride can precipitate or create incompatibility risks with phosphate and carbonate species. Formulators must evaluate precipitation, pH drift, visual appearance, extractables and leachables, and container interaction over the intended shelf life.

A proprietary opportunity may exist where a company develops a stable, ready-to-use calcium chloride product with a validated container system, improved handling profile, or reduced preparation burden. The product would still face substantial regulatory scrutiny because the active ingredient is well known and the clinical use is established.

Parenteral nutrition

Calcium is a standard component of parenteral nutrition, but calcium chloride is not interchangeable with calcium gluconate in every formulation. The calcium salt affects elemental calcium concentration, anion load, pH, compatibility, and precipitation risk.

In parenteral nutrition, the core technical issue is calcium-phosphate compatibility. The risk depends on calcium and phosphate concentrations, pH, amino acid composition, temperature, order of mixing, storage duration, and container conditions. A commercial formulation strategy may focus on a validated calcium delivery system, automated compounding controls, or a premixed presentation rather than on calcium chloride alone.

Biologics and cell-based manufacturing

Calcium chloride has process applications in molecular biology, cell culture, transfection, viral vector production, and protein processing. In these settings, the material may not remain in the final drug product.

Commercial value increases when the supplier can provide:

• GMP documentation.
• Low endotoxin specifications.
• Defined trace-metal limits.
• Low bioburden or sterile-grade material.
• Lot-to-lot consistency.
• Animal-origin-free manufacturing.
• Change-control support.
• Global regulatory documentation.
• Supply continuity for clinical and commercial batches.

For cell and gene therapy manufacturers, a calcium chloride product used during manufacturing may fall within the sponsor’s raw-material qualification program. The manufacturing material can become operationally critical even when it is absent from the final dose.

How strong is the calcium chloride patent estate?

The direct patent estate for calcium chloride is weak because the compound is an established inorganic salt with no meaningful new-molecule exclusivity.

IP category	Expected strength	Commercial assessment
Composition-of-matter patents	Very low	Calcium chloride is an old, well-characterized compound
New chemical entity exclusivity	None	Not applicable
Basic formulation patents	Low	Concentration and conventional excipients may be difficult to protect
Device and packaging patents	Moderate	Ready-to-use systems, administration devices, and closure technologies may be protectable
Manufacturing-process patents	Low to moderate	Value depends on a novel, reproducible process
Biologic process-use patents	Moderate	Protection may attach to a defined production workflow
Trade secrets	Moderate	Impurity control, sterilization, and compatibility data can be commercially important
Trademark and supply qualification	Moderate	Brand, reliability, and approved-source status can support pricing

The strongest defensible position is usually a combination of formulation-specific patent claims, process claims, proprietary packaging, regulatory documentation, and customer qualification. A patent directed only to calcium chloride in a conventional aqueous injection would face meaningful validity and obviousness risk.

Patent searches should cover calcium chloride, calcium chloride dihydrate, calcium ion formulations, parenteral nutrition, electrolyte replacement, calcium-phosphate compatibility, hydrogels, cell culture, viral vectors, and sterile container systems. Relevant claims may be filed under a formulation owner, contract manufacturer, medical-device company, or biologics platform company rather than under the calcium chloride supplier’s name.

What is the Orange Book status of calcium chloride?

The FDA Orange Book is relevant to approved drug products and listed patent or exclusivity information, but it is not a comprehensive record of all calcium chloride commercial products or all possible intellectual property.

For conventional calcium chloride injections:

• New chemical entity exclusivity is not expected.
• Product-specific patent protection is generally limited.
• Paragraph IV litigation risk is usually low unless an innovator product has listed patents.
• ANDA competition is more likely to focus on manufacturing, supply, labeling, and market availability than on molecular patent barriers.
• An applicant must still satisfy applicable quality, bioequivalence, labeling, sterility, and manufacturing requirements.

The Orange Book should be reviewed product by product because calcium chloride may appear under different sponsors, concentrations, dosage forms, and regulatory pathways [3]. A particular listed product may have no patents, while a differentiated delivery system could carry device or formulation claims.

When does calcium chloride lose exclusivity?

Calcium chloride does not have a typical branded-drug exclusivity timeline. The compound has been used in medicine for many decades, so practical market entry is governed by regulatory approval and manufacturing capability rather than loss of chemical exclusivity.

Exclusivity profile

Exclusivity type	Calcium chloride assessment
New chemical entity exclusivity	Not applicable
Orphan-drug exclusivity	Product- and indication-specific; not inherent to calcium chloride
Pediatric exclusivity	Possible only if separately granted to an eligible product
Qualified infectious disease exclusivity	Not applicable to ordinary calcium chloride products
Data exclusivity	Depends on the regulatory submission, not the compound alone
Patent term extension	Not expected for the old compound
Listed formulation patents	Possible but generally narrow
Device patents	Possible for delivery systems

Generic or follow-on entry can occur when a sponsor has an approvable product, suitable manufacturing capacity, and compliant labeling. The absence of a strong patent barrier does not eliminate practical barriers such as sterile facility availability, component sourcing, validation, inspection readiness, and low market margins.

Which companies are challenging calcium chloride products?

The market is generally fragmented among injectable-drug manufacturers, hospital-supply companies, generic manufacturers, and contract manufacturers. Competition is product-specific rather than driven by a single central patent dispute.

Relevant competitive groups include:

• Generic injectable manufacturers.
• Hospital and emergency-medicine suppliers.
• Large contract development and manufacturing organizations.
• Parenteral nutrition suppliers.
• Specialty electrolyte manufacturers.
• Pharmaceutical-grade chemical suppliers.
• Biologics raw-material vendors.

Publicly visible Paragraph IV activity is unlikely to be the main competitive mechanism for conventional calcium chloride. Suppliers typically compete through product availability, vial or syringe format, quality record, pricing, shortage performance, and institutional contracts.

What patent litigation affects calcium chloride?

Calcium chloride itself is unlikely to generate significant standalone patent litigation. Litigation exposure is more plausible in adjacent areas:

• Ready-to-use injectable delivery systems.
• Premixed parenteral nutrition.
• Calcium-containing depot formulations.
• Calcium-cross-linked hydrogels.
• Cell and gene therapy manufacturing processes.
• Combination products with proprietary administration devices.
• Packaging systems designed to reduce contamination or preparation error.

A freedom-to-operate review should separate claims directed to the calcium salt from claims directed to the dosage form, manufacturing sequence, device, or therapeutic method.

What generic launch risks exist for calcium chloride?

A generic calcium chloride launch has relatively low patent risk but meaningful execution risk.

Regulatory risks

A sponsor must address:

• Sterility assurance.
• Endotoxin control.
• Particulate matter.
• Assay and impurity specifications.
• pH and osmolality.
• Container closure integrity.
• Extractables and leachables.
• Stability under shipping conditions.
• Labeling for intravenous administration.
• Compatibility and dilution instructions.
• Manufacturing-site inspection readiness.

FDA injectable-drug guidance places significant emphasis on quality risk management and sterile manufacturing controls [4].

Commercial risks

The market can be difficult because:

• Unit prices are low.
• Hospital purchasing is consolidated.
• Supply contracts may reward redundancy rather than innovation.
• Product substitution can be straightforward.
• Demand is episodic in emergency medicine.
• Shortages can create abrupt but temporary pricing opportunities.
• A new entrant may need multiple concentrations and presentations to achieve meaningful scale.

The strongest launch strategy is usually a portfolio approach involving 10% injection, alternative vial sizes, prefilled or ready-to-use options where technically and economically justified, and reliable institutional distribution.

What commercial opportunities exist for calcium chloride excipients?

GMP-grade calcium chloride for biologics

Biologics manufacturers increasingly require stronger raw-material documentation. A supplier can differentiate through:

• Pharmaceutical-grade certificates of analysis.
• Elemental impurity testing aligned with ICH Q3D.
• Endotoxin and bioburden control.
• Animal-origin-free status.
• Sterile or low-bioburden grades.
• Multi-site manufacturing.
• Regulatory change notification.
• Supply agreements with reserved capacity.

The product may command a premium over industrial or food-grade calcium chloride if it reduces sponsor qualification work and batch-release risk.

Ready-to-use emergency presentations

Hospitals may value products that reduce bedside preparation. Commercial options include:

• Unit-dose vials.
• Prefilled syringes.
• Plastic containers with improved break resistance.
• Standardized emergency kits.
• Barcode-enabled institutional packaging.
• Concentration-specific products designed to reduce medication errors.

These opportunities are more likely to generate device, packaging, or process IP than active-ingredient patents.

Parenteral nutrition platforms

A supplier could develop calcium chloride products optimized for automated compounding systems and compatibility with defined parenteral nutrition formulations. The defensible asset would be the validated formulation and compounding protocol, supported by stability and precipitation data.

Specialty biomaterials

Calcium chloride can cross-link alginate and related polymers. Commercial opportunities include drug-delivery matrices, wound-care systems, injectable hydrogels, and tissue-engineering materials. In these markets, calcium chloride is usually one component of a broader platform. Patent value comes from polymer composition, cross-linking conditions, release kinetics, and clinical application.

How does calcium chloride compare with calcium gluconate?

Calcium chloride delivers more elemental calcium per unit mass than calcium gluconate. This supports smaller-volume emergency dosing but increases tissue-injury risk with extravasation.

Attribute	Calcium chloride	Calcium gluconate
Elemental calcium concentration	Higher	Lower
Typical emergency use	Rapid calcium replacement in selected settings	Common replacement option
Tissue injury risk	Higher if extravasated	Generally lower
Volume efficiency	Strong	Weaker
Formulation tolerance	Requires careful compatibility control	Often easier for routine replacement
Patent opportunity	Low for active ingredient	Low for active ingredient
Commercial differentiation	Packaging, delivery, supply reliability	Product presentation and institutional positioning

The choice between the salts depends on clinical indication, route, urgency, concentration, venous access, and institutional protocol. A commercial product should not position calcium chloride as a universal substitute for calcium gluconate.

What geographic coverage and manufacturing barriers matter?

Calcium chloride is globally available, but pharmaceutical supply is constrained by quality requirements rather than chemical scarcity.

Key geographic considerations include:

• Local registration requirements for injectable products.
• Pharmacopeial compliance in the United States, Europe, Japan, and other markets.
• Import controls for sterile drug products.
• Approved-site and approved-source requirements.
• Regional demand from hospitals and parenteral nutrition manufacturers.
• Availability of qualified glass, plastic, and elastomer components.
• Transport controls for temperature and moisture-sensitive materials.
• Redundant production for shortage mitigation.

Manufacturing barriers include validated dissolution, filtration, filling, terminal sterilization where suitable, aseptic processing, visual inspection, container closure testing, and stability programs. Calcium chloride’s corrosive and hygroscopic properties can affect equipment selection and material compatibility.

What licensing deals are relevant to calcium chloride?

Large upfront licensing transactions are unlikely for unmodified calcium chloride. The more relevant commercial structures are:

• Long-term supply agreements.
• Dual-source qualification contracts.
• Contract manufacturing agreements.
• Private-label injectable arrangements.
• Co-development of prefilled syringes or emergency kits.
• Raw-material master supply agreements for biologics.
• Technology licenses for packaging or administration devices.
• Formulation licenses for calcium-containing hydrogels or parenteral nutrition systems.

The contract value is driven by supply assurance, regulatory support, reserved capacity, and product differentiation. A supplier with an approved sterile product and reliable shortage performance may have more negotiating leverage than a supplier with a weakly differentiated patent.

What revenue exposure and launch scenarios should investors assess?

Calcium chloride revenue is usually exposed to volume, institutional contracts, and supply continuity rather than patent-protected pricing.

Base-case generic launch

A conventional 10% injection enters a competitive market. Pricing is limited, and success depends on manufacturing cost, reliable supply, and distribution access.

Shortage-driven launch

A temporary shortage increases demand for alternate suppliers. Revenue can rise quickly, but the opportunity may reverse when incumbent supply returns.

Premium presentation launch

A ready-to-use syringe, emergency kit, or safer handling system commands a higher price. The product requires human-factors validation, device development, packaging investment, and potentially a more complex regulatory pathway.

Biologics raw-material strategy

A GMP-grade calcium chloride product is qualified by biologics manufacturers. Revenue grows through recurring supply agreements and switching costs associated with requalification.

Platform formulation strategy

Calcium chloride supports a proprietary hydrogel, cell-processing reagent, or parenteral nutrition system. The highest IP value lies in the platform and process, not the salt.

Key Takeaways

• Calcium chloride is primarily an established injectable active ingredient, with selective excipient and process-use applications.
• Direct composition patents and new-drug exclusivity are effectively unavailable for the old inorganic salt.
• The strongest commercial protections are formulation know-how, sterile manufacturing capability, packaging, regulatory documentation, and supply reliability.
• Orange Book and Paragraph IV risk is generally low for conventional calcium chloride injections, but product-specific review remains necessary.
• The most attractive opportunities are GMP-grade biologics raw materials, ready-to-use emergency products, parenteral nutrition systems, and calcium-cross-linked biomaterials.
• Calcium chloride delivers more elemental calcium than calcium gluconate but has greater administration and extravasation risks.
• Manufacturing and quality systems, rather than chemical availability, are the main barriers to entry.
• Licensing opportunities are more likely to involve supply, packaging, devices, and formulation platforms than the calcium chloride molecule.

FAQs About Calcium Chloride Pharmaceutical and Excipient Opportunities

Can calcium chloride be used in injectable drug formulations?

Yes. It is widely used as an injectable active ingredient and can also function as a calcium source or formulation modifier. Compatibility, sterility, concentration, and administration-route requirements must be evaluated for each product.

Does calcium chloride have biosimilar risk?

No. Calcium chloride is a small inorganic compound, not a biologic. Biosimilar regulation does not apply. Competition occurs through generic, abbreviated, or conventional drug-product pathways.

Can calcium chloride be patented as a pharmaceutical excipient?

The compound itself is unlikely to support meaningful new composition claims. Patentability may arise from a specific formulation, manufacturing process, delivery device, packaging system, hydrogel, or biologic-production method.

Is calcium chloride suitable for parenteral nutrition?

It can be used in parenteral nutrition, but calcium-phosphate compatibility and precipitation risk require formulation-specific evaluation. Calcium gluconate may be selected in some products because it provides a different compatibility and elemental-calcium profile.

What is the best commercial entry strategy for calcium chloride?

The strongest strategy combines a compliant sterile product or GMP raw material with reliable supply, institutional distribution, differentiated packaging, and documented compatibility or process performance. A molecule-only strategy has limited pricing power.

References

1. U.S. Food and Drug Administration. (2023). Calcium chloride injection, USP: Prescribing information. DailyMed.

2. U.S. Food and Drug Administration. (2024). Inactive Ingredient Database. FDA Center for Drug Evaluation and Research.

3. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. 44th ed. FDA.

4. U.S. Food and Drug Administration. (2004). Sterile drug products produced by aseptic processing: Current good manufacturing practice. Guidance for Industry.

5. United States Pharmacopeial Convention. (2024). United States Pharmacopeia and National Formulary: Calcium chloride and calcium chloride injection monographs. USP-NF.

6. International Council for Harmonisation. (2019). ICH Q3D(R2): Guideline for elemental impurities. ICH.

7. U.S. Food and Drug Administration. (2019). Quality considerations for clinical research and development of generic drug products. FDA Center for Drug Evaluation and Research.